Baxter International Inc. (BAX) Net Profit Margin: -9.70%
Is Baxter International Inc.’s net profit margin high or low?
Baxter International Inc.'s net profit margin of -9.70% is 950% below its 5-year average of 1.14%, near the low end of its 5-year range (-24.19%–25.64%).
As of Thursday, June 11, 2026. 32.79% below its 12-month average of -7.30%.
BAX Net Profit Margin Chart
BAX Average Net Profit Margin Chart
BAX Current vs Average Net Profit Margin Chart
BAX Net Profit Margin Metrics
NET PROFIT MARGIN
-9.70%
NET PROFIT MARGIN AVG TTM
-7.30%
NET PROFIT MARGIN AVG 3Y
-3.29%
NET PROFIT MARGIN AVG 5Y
1.14%
NET PROFIT MARGIN AVG 10Y
8.53%
NET PROFIT MARGIN AVG 15Y
11.39%
NET PROFIT MARGIN AVG 20Y
12.12%
CURRENT VS TTM AVG
-32.79%
CURRENT VS 3Y AVG
-194.83%
CURRENT VS 5Y AVG
-949.64%
CURRENT VS 10Y AVG
-213.70%
CURRENT VS 15Y AVG
-185.15%
CURRENT VS 20Y AVG
-180.06%
BAX Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Baxter International Inc. (BAX) | $10.49B | -9.70% | -7.30% | -3.29% | 1.14% |
| Charles River Laboratories International, Inc. (CRL) | $8.94B | -4.59% | -1.67% | 5.09% | 7.31% |
| Align Technology, Inc. (ALGN) | $12.27B | 10.50% | 10.36% | 10.48% | 22.21% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.92B | 6.52% | -21.22% | -48.94% | 16.61% |
| Hims & Hers Health, Inc. (HIMS) | $6.19B | -0.56% | 7.00% | -0.29% | -8.82% |
| Hologic, Inc. (HOLX) | $16.97B | 13.18% | 16.70% | 17.87% | 22.37% |
| Moderna, Inc. (MRNA) | $18.71B | -143.55% | -128.24% | -70.25% | -50.87% |
| BioNTech SE (BNTX) | $22.39B | -44.73% | -31.89% | 3.77% | 12.08% |
| Mettler-Toledo International Inc. (MTD) | $22.82B | 21.40% | 21.94% | 21.74% | 21.20% |
| Waters Corporation (WAT) | $23.21B | 11.91% | 20.93% | 21.85% | 22.39% |
Margin Comparison
Operating Margin
-2.6%
Net Profit Margin
-9.7%
Baxter International Inc. Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Baxter International Inc. Net Profit Margin FAQ
- What is the net profit margin for Baxter International Inc. (BAX)?
- The net profit margin for BAX stock is -9.70%.
- Is Baxter International Inc.'s net profit margin high or low?
- Baxter International Inc.'s net profit margin of -9.70% is 950% below its 5-year average of 1.14%, near the low end of its 5-year range (-24.19%–25.64%).
- What is the TTM average net profit margin for Baxter International Inc. (BAX)?
- The TTM average net profit margin for BAX stock is -7.30%.
- What is the 3Y average net profit margin for Baxter International Inc. (BAX)?
- The 3Y average net profit margin for BAX stock is -3.29%.
- What is the 5Y average net profit margin for Baxter International Inc. (BAX)?
- The 5Y average net profit margin for BAX stock is 1.14%.
- What is the 10Y average net profit margin for Baxter International Inc. (BAX)?
- The 10Y average net profit margin for BAX stock is 8.53%.
- What is the 15Y average net profit margin for Baxter International Inc. (BAX)?
- The 15Y average net profit margin for BAX stock is 11.39%.
- What is the 20Y average net profit margin for Baxter International Inc. (BAX)?
- The 20Y average net profit margin for BAX stock is 12.12%.
Baxter International Inc. Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | -8.51% |
| 2024-12-31 | -6.10% |
| 2023-12-31 | 25.64% |
| 2022-12-31 | -24.19% |
| 2021-12-31 | 10.57% |
| 2020-12-31 | 9.44% |
| 2019-12-31 | 8.81% |
| 2018-12-31 | 13.93% |
| 2017-12-31 | 5.69% |
| 2016-12-31 | 48.85% |
| 2015-12-31 | 9.71% |
| 2014-12-31 | 23.30% |
| 2013-12-31 | 21.37% |
| 2012-12-31 | 16.69% |
| 2011-12-31 | 16.01% |
| 2010-12-31 | 11.06% |
| 2009-12-31 | 17.55% |
| 2008-12-31 | 16.31% |
| 2007-12-31 | 15.16% |
| 2006-12-31 | 13.45% |
| 2005-12-31 | 9.71% |
| 2004-12-31 | 4.08% |
| 2003-12-31 | 9.73% |
| 2002-12-31 | 9.52% |
| 2001-12-31 | 8.32% |
| 2000-12-31 | 11.05% |
| 1999-12-31 | 12.49% |
| 1998-12-31 | 5.52% |
| 1997-12-31 | 5.70% |
| 1996-12-31 | 12.30% |
Related Metrics
About Baxter International Inc.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Andrew Hider